John H. Sampson

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

David A. Reardon, Alba A. Brandes, Antonio Omuro et al. · JAMA Oncology · 2020 · 1.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Journal of Clinical Oncology · 2007 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

John H. Sampson, Amy B. Heimberger, Gary E. Archer et al. · Journal of Clinical Oncology · 2010 · 808 citations · Full text

Medicine, Immunology, Oncology +17

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Annick Desjardins, Matthias Gromeier, James E. Herndon et al. · New England Journal of Medicine · 2018 · 802 citations · Full text

Pharmacy, Infectious Diseases, Oncology +17